GSK

1,473

+0.27%↑

GSK

1,473

+0.27%↑

GSK

1,473

+0.27%↑

GSK

1,473

+0.27%↑

GSK

1,473

+0.27%↑

Search

AstraZeneca PLC

Închisă

SectorSănătate

12,076 -1.15

Rezumat

Modificarea prețului

24h

Curent

Minim

12076

Maxim

12198

Indicatori cheie

By Trading Economics

Venit

211M

3.1B

Vânzări

1.3B

15B

P/E

Medie Sector

30.153

35.733

Randament dividend

2.65

Marjă de profit

21.067

Angajați

94,300

EBITDA

18M

5.1B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+12.23% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

2.65%

3.13%

Următoarele câștiguri

6 nov. 2025

Data viitoare de dividende

8 sept. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

17B

184B

Deschiderea anterioară

12077.15

Închiderea anterioară

12076

Sentimentul știrilor

By Acuity

39%

61%

132 / 371 Clasament în Healthcare

AstraZeneca PLC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 iul. 2025, 08:08 UTC

Câștiguri

AstraZeneca Books Record Quarterly Revenue as U.S, Oncology Boosts Growth -- Update

29 iul. 2025, 06:46 UTC

Câștiguri

AstraZeneca Books Record Quarterly Revenue as Oncology Boosts Growth

8 aug. 2025, 10:51 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

1 aug. 2025, 11:10 UTC

Acțiuni populare

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

29 iul. 2025, 11:02 UTC

Câștiguri

AstraZeneca 2Q Adj EPS $2.17 >AZN.LN

29 iul. 2025, 11:02 UTC

Câștiguri

AstraZeneca 2Q EPS $1.58 >AZN.LN

29 iul. 2025, 11:01 UTC

Câștiguri

AstraZeneca 2Q Rev $14.5B >AZN.LN

29 iul. 2025, 11:00 UTC

Câștiguri

AstraZeneca Results: H1 and Q2 2025

29 iul. 2025, 08:00 UTC

Market Talk
Câștiguri

AstraZeneca Holding Back on a Guidance Upgrade Disappoints -- Market Talk

29 iul. 2025, 07:53 UTC

Market Talk
Câștiguri

AstraZeneca Continues to Deliver Under U.S. Tariff Threat -- Market Talk

29 iul. 2025, 07:26 UTC

Market Talk
Câștiguri

AstraZeneca Shares Look Undervalued -- Market Talk

29 iul. 2025, 06:03 UTC

Câștiguri

Analysts Saw AstraZeneca 2Q Total Revenue at $14.15B

29 iul. 2025, 06:03 UTC

Câștiguri

AstraZeneca 2Q Total Revenue $14.46B

29 iul. 2025, 06:03 UTC

Câștiguri

Analysts Saw AstraZeneca 2Q Core EPS at $2.16

29 iul. 2025, 06:03 UTC

Câștiguri

AstraZeneca 2Q Core EPS $2.17

29 iul. 2025, 06:02 UTC

Câștiguri

AstraZeneca Sees Core EPS Increasing by a Low Double-Digit Percentage

29 iul. 2025, 06:02 UTC

Câștiguri

AstraZeneca Sees Total Revenue Increasing by a High Single-Digit Percentage

29 iul. 2025, 06:02 UTC

Câștiguri

AstraZeneca Backs 2025 View

29 iul. 2025, 06:00 UTC

Câștiguri

AstraZeneca PLC 2Q Rev $14.46B

29 iul. 2025, 06:00 UTC

Câștiguri

AstraZeneca PLC 2Q Adj EPS $2.17

29 iul. 2025, 06:00 UTC

Câștiguri

AstraZeneca PLC 2Q Pretax Pft $3.13B

29 iul. 2025, 06:00 UTC

Câștiguri

AstraZeneca PLC 2Q Net Pft $2.45B

29 iul. 2025, 06:00 UTC

Câștiguri

AstraZeneca PLC 2Q Oper Pft $3.51B

29 iul. 2025, 06:00 UTC

Câștiguri

AstraZeneca PLC 2Q EPS $1.57

28 iul. 2025, 10:51 UTC

Market Talk

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

22 iul. 2025, 10:19 UTC

Market Talk

AstraZeneca's Big U.S. Spending Plans Could Put NY Listing on the Table -- Market Talk

22 iul. 2025, 09:34 UTC

Acțiuni populare

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

9 iul. 2025, 10:59 UTC

Market Talk

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

9 iul. 2025, 09:17 UTC

Acțiuni populare

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

28 mai 2025, 18:09 UTC

Câștiguri

Heart Disease Could Be a Goner When These New -2-

Comparație

Modificare preț

AstraZeneca PLC Așteptări

Obiectiv de preț

By TipRanks

12.23% sus

Prognoză pe 12 luni

Medie 13,678.18 GBX  12.23%

Maxim 18,000 GBX

Minim 10,900 GBX

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAstraZeneca PLC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

12 ratings

9

Cumpărare

3

Păstrare

0

Vânzare

Sentiment

By Acuity

132 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
help-icon Live chat